🤖 This page was written by AI and reviewed by a human. 2026-07-15. Version 0.18
Richard Sackler
Status
Born in 1945 (age –).
Criminal status: No personal convictions; Purdue Pharma pleaded guilty to three federal felony charges in November 2020 — fraud conspiracy and two counts of anti-kickback conspiracy — under Sackler family leadership. Multiple state and federal civil suits named Richard Sackler personally. The Sackler family reached a $7.4 billion civil settlement in 2025, which a federal bankruptcy judge formally confirmed in November 2025 and which took legal effect in May 2026.
Summary
Richard Sackler is the son of Raymond Sackler, one of the three brothers who founded Purdue Pharma, the Connecticut-based pharmaceutical company that manufactured OxyContin. He served as Purdue's president from 1999 to 2003 and co-chairman of its board from 2004 to 2007, and sat on the board until 2018.
He was the driving force behind OxyContin's development and launch in 1995-1996, a drug widely credited with igniting the American opioid epidemic. Multiple state attorneys general named him personally in lawsuits alleging he directed the fraudulent marketing of the drug, concealed its addictive properties from doctors, and profited massively as overdose deaths rose.
Ownership
Sackler held his Purdue Pharma stake through the family's complex trust and holding company structures, some registered in offshore tax havens. Between 2008 and 2016, the Sackler family extracted approximately $10.4 billion from Purdue in dividends and distributions, draining most of the company's assets before it filed for bankruptcy in 2019.
Purdue Pharma shut down and ceased operations in May 2026 as a condition of the settlement. Its manufacturing operations transferred to Knoa Pharma, a new public benefit corporation wholly owned by an independent nonprofit foundation; the Sackler family has no ownership stake or role in the new company and is permanently barred from selling opioids in the United States.
Separately from Purdue, Richard Sackler was listed as an inventor on a 2018 patent for a fast-dissolving buprenorphine wafer designed to treat opioid addiction.
Family & Heirs
Richard Sackler is the son of Raymond Sackler (1920-2017), one of the three founding brothers of Purdue Pharma. His wife, Beth Sackler, serves as vice president of the Richard and Beth Sackler Foundation, which Richard founded and leads as president and treasurer.
His son David Sackler also served on the board of Purdue Pharma, and the Yale Daily News has described David as having played an active role in board-level decisions. Jonathan Sackler, another member of Raymond's branch of the family who co-donated the Yale professorship with Richard, died in 2020.
Evidence
1996-01-01 - 😈 - At OxyContin's launch, Sackler told his sales force there would be "a blizzard of prescriptions that will bury the competition"
2001-01-01 - 😈 - In emails, Sackler called opioid addicts "victimizers" and "criminals" as overdose deaths mounted
2009-01-01 - 😇 - Richard and Jonathan Sackler donated $3 million to fund a Yale School of Medicine professorship in internal medicine
2016-01-01 - 😈 - The Sackler family extracted $10.4 billion from Purdue in dividends and distributions from 2008 to 2016 as opioid overdose deaths soared
2019-08-27 - 😈 - In his only known sworn testimony, Sackler denied his family played any role in more than 200,000 prescription opioid overdose deaths
Analysis
Richard Sackler's record is dominated by a single sustained enterprise: building and protecting a system that addicted millions of Americans to OxyContin, extracted tens of billions of dollars in profit, and then shielded that wealth from accountability as people died. He personally directed the misleading marketing strategy — suppressing information about the drug's potency, instructing sales staff to downplay addiction risks, and driving prescriptions to grow through aggressive sales incentives. When the human cost became undeniable, he blamed the victims in writing, calling people addicted to his company's product "victimizers."
More than 500,000 Americans have died from opioid overdoses since OxyContin's launch, a crisis public health researchers trace in significant part to Purdue's marketing practices. Sackler's family extracted approximately $10.4 billion from Purdue during the years of greatest harm, moved substantial wealth offshore before bankruptcy, and spent years fighting in court to suppress his own testimony. In 2018, Sackler was even named as an inventor on a patent for a drug to treat the same opioid addiction his company's product helped cause.
The $7.4 billion settlement, while the largest paid by individuals in US history, represents a fraction of what the family extracted and is paid out over 15 years.
Questions
The settlement releases the Sackler family from most civil liability in exchange for payments spread across 15 years — meaning the family retains substantial remaining wealth. Whether this resolution is proportionate to the scale of harm remains a genuine question. The Supreme Court in 2024 overturned an earlier settlement that would have provided broader immunity from future lawsuits, and the newer deal still allows some victims to pursue individual claims.
The opioid epidemic did not begin or end with Purdue — distributors, pharmacy chains, other manufacturers, and regulatory failures all contributed. Whether one family's decisions were the decisive factor, or whether the epidemic would have happened through other channels regardless, is debated among public health researchers. The settlements and guilty pleas establish legal facts; they do not resolve questions about how much of the total harm is attributable to any single actor.
Redemption Arc
Sackler acknowledged in a 2019 deposition that his views on addiction had "evolved" since 2001. The settlement he agreed to includes a provision allowing institutions to remove the Sackler name from buildings without legal retaliation. The agreement explicitly does not require the family to admit wrongdoing, and the family's public statements have consistently denied that the company acted illegally.